249 related articles for article (PubMed ID: 16454749)
21. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.
Yang S; Tsang KY; Schlom J
Clin Cancer Res; 2005 Aug; 11(15):5603-15. PubMed ID: 16061879
[TBL] [Abstract][Full Text] [Related]
22. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2004 Feb; 10(3):1090-9. PubMed ID: 14871989
[TBL] [Abstract][Full Text] [Related]
23. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
24. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Palena C; Foon KA; Panicali D; Yafal AG; Chinsangaram J; Hodge JW; Schlom J; Tsang KY
Blood; 2005 Nov; 106(10):3515-23. PubMed ID: 16081691
[TBL] [Abstract][Full Text] [Related]
25. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL
Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356
[No Abstract] [Full Text] [Related]
26. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
Hodge JW; Grosenbach DW; Rad AN; Giuliano M; Sabzevari H; Schlom J
Vaccine; 2001 May; 19(25-26):3552-67. PubMed ID: 11348723
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.
Kudo-Saito C; Garnett CT; Wansley EK; Schlom J; Hodge JW
Cancer Immunol Immunother; 2007 Dec; 56(12):1897-910. PubMed ID: 17503041
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
[TBL] [Abstract][Full Text] [Related]
29. A triad of costimulatory molecules synergize to amplify T-cell activation.
Hodge JW; Sabzevari H; Yafal AG; Gritz L; Lorenz MG; Schlom J
Cancer Res; 1999 Nov; 59(22):5800-7. PubMed ID: 10582702
[TBL] [Abstract][Full Text] [Related]
30. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.
Duggan MC; Jochems C; Donahue RN; Richards J; Karpa V; Foust E; Paul B; Brooks T; Tridandapani S; Olencki T; Pan X; Lesinski GB; Schlom J; Carson Iii WE
Cancer Immunol Immunother; 2016 Nov; 65(11):1353-1364. PubMed ID: 27581603
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
Madan RA; Bilusic M; Heery C; Schlom J; Gulley JL
Semin Oncol; 2012 Jun; 39(3):296-304. PubMed ID: 22595052
[TBL] [Abstract][Full Text] [Related]
33. Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
Morse MA
Curr Opin Mol Ther; 2001 Aug; 3(4):407-12. PubMed ID: 11525565
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of the intratumoral injection of fowlpox vectors expressing a triad of costimulatory molecules and granulocyte/macrophage colony stimulating factor in mesothelioma.
Triozzi PL; Aldrich W; Allen KO; Lima J; Shaw DR; Strong TV
Int J Cancer; 2005 Jan; 113(3):406-14. PubMed ID: 15455351
[TBL] [Abstract][Full Text] [Related]
35. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
36. Carcinoembryonic antigen-based vaccines.
Marshall J
Semin Oncol; 2003 Jun; 30(3 Suppl 8):30-6. PubMed ID: 12881810
[TBL] [Abstract][Full Text] [Related]
37. Cancer therapy and vaccination.
Aly HA
J Immunol Methods; 2012 Aug; 382(1-2):1-23. PubMed ID: 22658969
[TBL] [Abstract][Full Text] [Related]
38. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
[TBL] [Abstract][Full Text] [Related]
39. Vaccines in the treatment of cancer.
Baltz JK
Am J Health Syst Pharm; 1995 Nov; 52(22):2574-85; quiz 2594-5. PubMed ID: 8590245
[TBL] [Abstract][Full Text] [Related]
40. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
DeMaria PJ; Lee-Wisdom K; Donahue RN; Madan RA; Karzai F; Schwab A; Palena C; Jochems C; Floudas C; Strauss J; Marté JL; Redman JM; Dombi E; Widemann B; Korchin B; Adams T; Pico-Navarro C; Heery C; Schlom J; Gulley JL; Bilusic M
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]